These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 24942635)

  • 1. Orexin/hypocretin based pharmacotherapies for the treatment of addiction: DORA or SORA?
    Khoo SY; Brown RM
    CNS Drugs; 2014 Aug; 28(8):713-30. PubMed ID: 24942635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutics development for addiction: Orexin-1 receptor antagonists.
    Perrey DA; Zhang Y
    Brain Res; 2020 Mar; 1731():145922. PubMed ID: 30148984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?
    Hoyer D; Jacobson LH
    Neuropeptides; 2013 Dec; 47(6):477-88. PubMed ID: 24215799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential role of the orexin reward system in future treatments for opioid drug abuse.
    Zarrabian S; Riahi E; Karimi S; Razavi Y; Haghparast A
    Brain Res; 2020 Mar; 1731():146028. PubMed ID: 30476469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orexin OX
    Jacobson LH; Chen S; Mir S; Hoyer D
    Curr Top Behav Neurosci; 2017; 33():105-136. PubMed ID: 27909987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders.
    Han Y; Yuan K; Zheng Y; Lu L
    Neurosci Bull; 2020 Apr; 36(4):432-448. PubMed ID: 31782044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Decade of Orexin/Hypocretin and Addiction: Where Are We Now?
    James MH; Mahler SV; Moorman DE; Aston-Jones G
    Curr Top Behav Neurosci; 2017; 33():247-281. PubMed ID: 28012090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cocaine abuse and midbrain circuits: Functional anatomy of hypocretin/orexin transmission and therapeutic prospect.
    Simmons SJ; Gentile TA
    Brain Res; 2020 Mar; 1731():146164. PubMed ID: 30796894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and development of orexin receptor antagonists as therapeutics for insomnia.
    Winrow CJ; Renger JJ
    Br J Pharmacol; 2014 Jan; 171(2):283-93. PubMed ID: 23731216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Suvorexant, a Dual Orexin/Hypocretin Receptor Antagonist, on Impulsive Behavior Associated with Cocaine.
    Gentile TA; Simmons SJ; Watson MN; Connelly KL; Brailoiu E; Zhang Y; Muschamp JW
    Neuropsychopharmacology; 2018 Apr; 43(5):1001-1009. PubMed ID: 28741623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of highly potent and selective orexin 1 receptor antagonists (1-SORAs) suitable for in vivo interrogation of orexin 1 receptor pharmacology.
    Stump CA; Cooke AJ; Bruno J; Cabalu TD; Gotter AL; Harell CM; Kuduk SD; McDonald TP; O'Brien J; Renger JJ; Williams PD; Winrow CJ; Coleman PJ
    Bioorg Med Chem Lett; 2016 Dec; 26(23):5809-5814. PubMed ID: 27818110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Orexin Receptor Antagonists: Historical Perspectives and Future Opportunities.
    Andrews SP; Aves SJ; Christopher JA; Nonoo R
    Curr Top Med Chem; 2016; 16(29):3438-3469. PubMed ID: 26416477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Insomnia-Addiction Positive Feedback Loop: Role of the Orexin System.
    Fragale JE; James MH; Avila JA; Spaeth AM; Aurora RN; Langleben D; Aston-Jones G
    Front Neurol Neurosci; 2021; 45():117-127. PubMed ID: 34052815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Orexin Receptor Antagonists in the Treatment of Depression: A Leading Article Summarising Pre-clinical and Clinical Studies.
    Fagan H; Jones E; Baldwin DS
    CNS Drugs; 2023 Jan; 37(1):1-12. PubMed ID: 36436175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of orexin receptors in the ventral tegmental area on acquisition and expression of morphine-induced conditioned place preference in the rats.
    Farahimanesh S; Zarrabian S; Haghparast A
    Neuropeptides; 2017 Dec; 66():45-51. PubMed ID: 28890208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of diazepane amide DORAs and 2-SORAs enabled by exploration of isosteric quinazoline replacements.
    Roecker AJ; Mercer SP; Bergman JM; Gilbert KF; Kuduk SD; Harrell CM; Garson SL; Fox SV; Gotter AL; Tannenbaum PL; Prueksaritanont T; Cabalu TD; Cui D; Lemaire W; Winrow CJ; Renger JJ; Coleman PJ
    Bioorg Med Chem Lett; 2015 Nov; 25(21):4992-4999. PubMed ID: 25613676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent perspectives on orexin/hypocretin promotion of addiction-related behaviors.
    Hopf FW
    Neuropharmacology; 2020 May; 168():108013. PubMed ID: 32092435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Introduction to the Special Issue: "Making orexin-based therapies for addiction a reality: What are the steps from here?".
    James MH; Aston-Jones G
    Brain Res; 2020 Mar; 1731():146665. PubMed ID: 31930996
    [No Abstract]   [Full Text] [Related]  

  • 19. Lateral hypothalamic orexin/hypocretin neurons: A role in reward-seeking and addiction.
    Aston-Jones G; Smith RJ; Sartor GC; Moorman DE; Massi L; Tahsili-Fahadan P; Richardson KA
    Brain Res; 2010 Feb; 1314():74-90. PubMed ID: 19815001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orexin receptors: multi-functional therapeutic targets for sleeping disorders, eating disorders, drug addiction, cancers and other physiological disorders.
    Xu TR; Yang Y; Ward R; Gao L; Liu Y
    Cell Signal; 2013 Dec; 25(12):2413-23. PubMed ID: 23917208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.